Drug intelligence / Profile preview

P1801

Development stage: Phase 1
Lead developer: PharmaEssentia
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

P1801 is a **recombinant humanized anti-PD-1 monoclonal antibody** being developed by PharmaEssentia for the treatment of advanced solid tumors. Its mechanism of action involves binding to the programmed cell death protein 1 (PD-1), thereby blocking the interaction between PD-1 and its ligands (PD-L1/PD-L2), which results in the enhancement of T cell-mediated immune responses against tumor cells. P1801 is currently in a Phase I clinical trial in Taiwan, being studied as sequential treatment following ropeginterferon alfa-2b (P1101)[1][7].

Other names: P1801P-1801P 1801

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on P1801.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P1801.

Explore the full profile